Publications by authors named "Ai Yoneda"
Article Synopsis
- - The study examined why some patients with type 1 macular neovascularization (MNV) successfully switched to faricimab after being unresponsive to intravitreal aflibercept (IVA).
- - Out of 43 patients analyzed, 32.6% experienced an extension of their treatment intervals by more than two weeks after switching to faricimab.
- - Factors contributing to successful treatment extension included shorter dosing intervals prior to switching, the absence of polypoidal lesions, and thinner central choroidal thickness.
Purpose: To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial treatment for treatment-naïve polypoidal choroidal vasculopathy.
Methods: We retrospectively reviewed 63 eyes of 61 patients with treatment-naïve polypoidal choroidal vasculopathy who had undergone at least 24 months of follow-up. In total, 43 eyes underwent intravitreal ranibizumab-photodynamic therapy combination therapy and 20 eyes underwent fixed-dosing intravitreal aflibercept monotherapy.
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros(®): tafluprost) has been reduced to balance corneal safety and preservative effectiveness (old formulation: 0.01%; new formulation: 0.001%).
View Article and Find Full Text PDF